Skip to content

Omnicell OMCL Proceeds from exercises of stock options and other stock issuances

Proceeds from exercises of stock options and other stock issuances at other companies

Baxter International logo
Baxter InternationalBAX
BrightSpring Health Services, Inc. logo
BrightSpring Health Services, Inc.BTSG
GE HealthCare Technologies logo
GE HealthCare TechnologiesGEHC
OSI Systems logo
OSI SystemsOSIS

Other financials

Income statement

See full
Revenue$309.9M+14.9%
Gross profit$140.4M+26.5%
Operating income$16.9M+245%
Net income$11.4M+262%
EPS (diluted)$0.25+267%

Balance sheet

See full
Cash & equivalents$291.0M-29.8%
Total debt$34.3M-23.1%
Total equity$1.3B0.0%
Total assets$2.0B-6.8%

Cash flow

See full
Operating cash flow$54.5M+110%
CapEx$12.4M+11.3%
Free cash flow$42.1M+185%

Valuation

See full
Market cap$1.8B-7.2%
Enterprise value$1.54B-0.4%
P/E116.4×
P/S1.5×-0.2×

Profitability

See full
Gross margin43.5%+0.4pp
Operating margin2.7%+1.8pp
Net margin1.7%+1.1pp
FCF margin9.3%-1.7pp

Returns & leverage

See full
Return on equity1.6%+1.1pp
Debt / equity0.0×
Current ratio1.5×+0.1×

Where this comes from

Reported directly by Omnicell in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Omnicell’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omnicell's proceeds from exercises of stock options and other stock issuances.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omnicell's proceeds from exercises of stock options and other stock issuances?
Omnicell (OMCL) reported proceeds from exercises of stock options and other stock issuances of $7.76M in Q1 2026.
How has Omnicell's proceeds from exercises of stock options and other stock issuances changed year-over-year?
Omnicell's proceeds from exercises of stock options and other stock issuances decreased by 6.1% year-over-year, from $8.27M to $7.76M.
What is the long-term trend for Omnicell's proceeds from exercises of stock options and other stock issuances?
Over 4 years (2021 to 2025), Omnicell's proceeds from exercises of stock options and other stock issuances has grown at a -29.3% compound annual growth rate (CAGR), from $67.35M to $16.87M.